Phase 1/2 Belantamab Mafodotin, a BCMA-targeted tubulin inhibitor ADC study

This trial evaluates escalating doses of belantamab alone or combined with belantamab mafodotin for relapsed/refractory multiple myeloma patients (≥4 prior therapies). Sponsored by GlaxoSmithKline, the multicentre study spans sites in Asia, Europe, and the Americas to define optimal dosing for this targeted therapy.